Chindia Alert: You’ll be Living in their World Very Soon
aims to alert you to the threats and opportunities that China and India present. China and India require serious attention; case of ‘hidden dragon and crouching tiger’.
Without this attention, governments, businesses and, indeed, individuals may find themselves at a great disadvantage sooner rather than later.
The POSTs (front webpages) are mainly 'cuttings' from reliable sources, updated continuously.
The PAGEs (see Tabs, above) attempt to make the information more meaningful by putting some structure to the information we have researched and assembled since 2006.
An antibody engineered from the animal’s immune system was found to neutralise the virus that causes Covid-19
American and Belgian researchers hope the discovery may help protect humans from the deadly illness
Winter the llama (front) lives on a farm operated by Ghent University’s Vlaams Institute for Biotechnology. Photo: Tim Coppens
A Belgian llama could hold the key to producing an antibody that neutralises the coronavirus that causes Covid-19.
More studies and clinical trials are needed to see if it can be used in humans to treat Covid-19, but the team of American and Belgian scientists who engineered the antibody said they were encouraged by their preliminary findings, which will be published in the journal Cell next week.
Jason McLellan, from the University of Texas at Austin and co-author of the study, described it as one of the “first antibodies known to neutralise Sars-CoV-2”, the official name for the virus.
“With antibody therapies, you’re directly giving somebody the protective antibodies and so, immediately after treatment, they should be protected,” he wrote in a press release.
“The antibodies could also be used to treat somebody who is already sick to lessen the severity of the disease.”
Winter the llama produced antibodies that proved effective against the Sars-CoV-2 virus. Photo: Tim Coppens
The scientists have been working on coronaviruses – including severe acute respiratory syndrome (Sars) and Middle East respiratory syndrome (Mers) – for years.
In 2016 they injected the llama, named Winter, with Sars and Mers in the hope of developing a treatment for the diseases.
“I thought this would be a small side project,” said Dorien De Vlieger from Ghent University in Belgium, who helped to isolate antibodies against coronaviruses from the llamas.
China’s race for a Covid-19 vaccine hits a hurdle – no outbreak at home
1 May 2020
“Now the scientific impact of this project became bigger than I could ever expect. It’s amazing how unpredictable viruses can be.”
A llama’s immune system produces two types of antibodies when it detects pathogens, one similar to human antibodies and one that is about a quarter of the size.
The antibodies produced by Winter were found to be effective in targeting the Sars virus’s spike protein, which allows it to bind to human cells.
Chinese firm ready to make 100 million Coronavirus vaccine doses if trials are successful
This year they decided to test the antibodies Winter had produced during the Sars experiment to see if it could prove effective against Covid-19.
Although it did bind itself to the Sars-CoV-2 virus it did so “weakly”, so the team then linked two copies of the antibody together to make it bind more effectively.
Oxford vaccine effective in monkeys, heading for mass production in India
30 Apr 2020
“That was exciting to me because I’d been working on this for years. But there wasn’t a big need for a coronavirus treatment then. This was just basic research,” said Daniel Wrapp from the University of Texas, a co-author of the study.
The smaller type of antibodies produced by llamas, called single-domain antibodies or nanobodies, can be used in an inhaler, according to Wrapp.
“That makes them potentially really interesting as a drug for a respiratory pathogen because you’re delivering it right to the site of infection,” said Wrapp.
Researchers created an antibody dubbed VHH-72Fc (blue) that binds tightly to the Sars-CoV-2 spike protein (pink, green and orange), blocking the virus from infecting cells. Photo: University of Texas at Austin
The researchers are preparing for more trials with hamsters or primates to further test the antibody, before taking it to human trials.
The main subject of the study, Winter the llama, is now four years old and lives on a farm operated by Ghent University’s Vlaams Institute for Biotechnologym which said it has around 130 other llamas and alpacas at the facility.
Six animals inoculated with vaccine candidate then exposed to virus did not catch Covid-19 after 28 days
Up to 60 million doses could be produced by Serum Institute of India this year
Microbiologist Elisa Granato gets an injection on Thursday as part of the first human trials in Britain for a potential coronavirus vaccine. Photo: University of Oxford via AP
A leading candidate for a Covid-19 vaccine has shown promising results in animal trials, and is expected to see mass production in India within months.
The Serum Institute of India, the world’s largest maker of vaccines by volume, said on Tuesday that it plans this year to produce up to 60 million doses of a potential vaccine developed by the University of Oxford, which is under clinical trial in Britain.
While the vaccine candidate, called “ChAdOx1 nCoV-19”, is yet to be proven to work against Covid-19, Serum decided to start manufacturing it as it had shown success in animal trials and had progressed to tests on humans, Serum Chief Executive Adar Poonawalla said.
Six rhesus macaque monkeys were inoculated with the vaccine candidate at the National Institutes of Health’s Rocky Mountain Laboratory in Montana last month, according to The New York Times.
Covid-19 vaccine trial starts in Oxford, but remdesivir treatment reportedly flops in China tests
The subjects were exposed afterwards to large quantities of the novel coronavirus, but all six remained healthy after more than 28 days, the newspaper reported, citing researcher Vincent Munster, who conducted the test.
More than 3 million people have been reported to be infected globally and over 210,000 have died from Covid-19, the respiratory disease caused by the coronavirus.
“They are a bunch of very qualified, great scientists [at Oxford] … That’s why we said we will go with this and that’s why we are confident,” Poonawalla told Reuters in a phone interview.
“Being a private limited company, not accountable to public investors or bankers, I can take a little risk and sideline some of the other commercial products and projects that I had planned in my existing facility,” Poonawalla said.
Bill Gates hopes his virus vaccine ‘manufacturing within a year’
27 Apr 2020
As many as 100 potential Covid-19 candidate vaccines are now under development by biotech and research teams around the world, and at least five of these are in preliminary testing in people in what are known as phase one clinical trials.
Poonawalla said he hoped trials of the Oxford vaccine, due to finish in about September, would be successful. Oxford scientists said last week the main focus of initial tests was to ascertain not only whether the vaccine worked but that it induced good immune responses and no unacceptable side effects.
Serum, owned by the Indian billionaire Cyrus Poonawalla, plans to make the vaccine at its two manufacturing plants in the western city of Pune, aiming to produce up to 400 million doses next year if all goes well, Poonawalla said.
“A majority of the vaccine, at least initially, would have to go to our countrymen before it goes abroad,” he said, adding that Serum would leave it to the Indian government to decide which countries would get how much of the vaccine and when.
Rhesus macaque monkeys are often used in animal testing because of their similarity to humans. Photo: AFP
Serum envisages a price of 1,000 rupees (US$14.70) per vaccine, but governments would give it to people without charge, he said.
He said Prime Minister Narendra Modi’s office was “very closely” involved in the vaccine production and the company is hoping the government will help foot the cost of making it.
Over roughly the next five months, Serum will spend some 300 million to 400 million rupees (US$4.4 million to US$5.9 million) on making around 3-5 million doses per month, he said. “[The government] are very happy to share some risk and fund something with us, but we haven’t really pencilled anything down yet,” Poonawalla said.
Coronavirus: clinical trial begins on third vaccine candidate in China
22 Apr 2020
Serum has also partnered with the US biotech firm Codagenix and Austria’s Themis on two other Covid-19 vaccine candidates and plans to announce a fourth alliance in a couple of weeks, he said.
Serum’s board last week also agreed to invest roughly 6 billion rupees (US$8.8 billion) on making a new manufacturing unit to solely produce coronavirus vaccines, Poonawalla said.
CHINDIA ALERT: You'll be living in their world, very soon 